During the recent session, Theseus Pharmaceuticals Inc. (NASDAQ:THRX)’s traded shares were 0.96 million. At the last check today, the stock’s price was $8.04, reflecting an intraday loss of -7.80% or -$0.68. The 52-week high for the THRX share is $14.77, that puts it down -83.71 from that peak though still a striking 50.12% gain since the share price plummeted to a 52-week low of $4.01. The company’s market capitalization is $373.04M, and the average intraday trading volume over the past 10 days was 0.11 million shares, and the average trade volume was 116.26K shares over the past three months.

Theseus Pharmaceuticals Inc. (THRX) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 1.40. THRX has a Sell rating from 0 analyst(s) out of 7 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 7 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.39.

Theseus Pharmaceuticals Inc. (NASDAQ:THRX) trade information

Theseus Pharmaceuticals Inc. (THRX) registered a -7.80% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -7.80% in intraday trading to $8.04 this Thursday, 05/25/23, hitting a weekly high. The stock’s 5-day price performance is -26.91%, and it has moved by -17.11% in 30 days. Based on these gigs, the overall price performance for the year is 6.63%. The short interest in Theseus Pharmaceuticals Inc. (NASDAQ:THRX) is 1.13 million shares and it means that shorts have 10.54 day(s) to cover.

The consensus price target of analysts on Wall Street is $22.29, which implies an increase of 63.93% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $18.00 and $24.00 respectively. As a result, THRX is trading at a discount of -198.51% off the target high and -123.88% off the low.

Theseus Pharmaceuticals Inc. (THRX) estimates and forecasts

Statistics show that Theseus Pharmaceuticals Inc. has underperformed its competitors in share price, compared to the industry in which it operates. Theseus Pharmaceuticals Inc. (THRX) shares have gone up 20.00% during the last six months, with a year-to-date growth rate less than the industry average at -20.61% against 11.70. Yet analysts are ramping up their growth forecast for the fiscal year 2023. Revenue is predicted to shrink -30.00% this quarter and then drop -10.50% in the quarter after that.

While earnings are projected to return -86.30% in 2023.

THRX Dividends

Theseus Pharmaceuticals Inc. is due to release its next quarterly earnings on May 11. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Theseus Pharmaceuticals Inc. (NASDAQ:THRX)’s Major holders

Theseus Pharmaceuticals Inc. insiders own 1.39% of total outstanding shares while institutional holders control 78.73%, with the float percentage being 79.84%. Orbimed Advisors LLC. is the largest shareholder of the company, while 76 institutions own stock in it. As of Mar 30, 2023, the company held over 17.23 million shares (or 39.55% of all shares), a total value of $137.35 million in shares.

The next largest institutional holding, with 3.59 million shares, is of Foresite Capital Management V, LLC’s that is approximately 8.23% of outstanding shares. At the market price on Mar 30, 2023, these shares were valued at $28.58 million.

Also, the Mutual Funds coming in first place with the largest holdings of Theseus Pharmaceuticals Inc. (THRX) shares are Fidelity Select Portfolios – Biotechnology and Price (T.Rowe) Health Sciences Fund. Data provided on Feb 27, 2023 indicates that Fidelity Select Portfolios – Biotechnology owns about 1.39 million shares. This amounts to just over 3.18 percent of the company’s overall shares, with a $11.04 million market value. The same data shows that the other fund manager holds slightly less at 1.01 million, or about 2.32% of the stock, which is worth about $8.04 million.